insights_auto
Зашто су деонице GIS порасле 2,64%?
Истражи детаљнијеchevron_right
GIS:FRA
Gilead Sciences, Inc
157,14 €
arrow_upward
+2,64%(+4,04) 1 Д
5. нов, 15:00:12 GMT+1 · EUR
search
Сви симболи
| Симбол | Цена | Промена | % промене |
|---|
insights_autoГенеришу се најзначајнији увиди за GIS...
Отвори
154,32 €
Високо
157,14 €
Ниско
154,24 €
Трж. капитализација
216,38 млрд.
Прос. количина
193,00
Количина
150,00
Највиша у 52 недеље
157,14 €
Најнижа у 52 недеље
100,42 €
Бр. запослених
17 хиљ.
Отвори
154,32 €
Високо
157,14 €
Ниско
154,24 €
Трж. капитализација
216,38 млрд.
Прос. количина
193,00
Количина
150,00
Највиша у 52 недеље
157,14 €
Најнижа у 52 недеље
100,42 €
Бр. запослених
17 хиљ.
Вести
Из веб-извора и од партнера за вести
Investing.com
·
пре 18 минута
Gilead presents PBC trial data, plans regulatory discussions
Yahoo Finance
·
пре 47 минута
Positive Phase 3 IDEAL Study Results Further Support Livdelzi®’s (Seladelpar) Impact on Achieving ALP Normalization Goals in Second-Line Treatment Across a Broad Population of People Living with Primary Biliary Cholangitis (PBC)
Yahoo Finance Singapore
·
пре 3 сата
Did Earnings Beat Just Shift Gilead Sciences' (GILD) Investment Narrative?
The Motley Fool
·
пре 5 сати
Gilead Sciences Has Raised Its Dividend for 11 Straight Years. Here's Why the Streak Looks Safe.
Профил
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
Gilead Sciences, Inc – основни подаци
Главни извршни директорДанијел О'деј
Запослени17 хиљ.
Основано22. 6. 1987.
СедиштеФостер Сити, Калифорнија, Сједињене Државе
Сектор-
Industry-
Веб-сајтgilead.com